ArrowMark Colorado Holdings’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $385K | Sell |
9,878
-25,000
| -72% | -$808K | 0.02% | 278 |
|
|
2026
Q1 | $1.13M | Sell |
34,878
-340
| -1% | -$10.9K | 0.03% | 244 |
|
|
2025
Q4 | $1.24M | Hold |
35,218
| – | – | 0.03% | 258 |
|
|
2025
Q3 | $926K | Sell |
35,218
-4,680
| -12% | -$140K | 0.02% | 254 |
|
|
2025
Q2 | $1.06M | Hold |
39,898
| – | – | 0.02% | 254 |
|
|
2025
Q1 | $964K | Hold |
39,898
| – | – | 0.02% | 252 |
|
|
2024
Q4 | $1.61M | Sell |
39,898
-25
| -0.1% | -$1.43K | 0.02% | 242 |
|
|
2024
Q3 | $2.53M | Hold |
39,923
| – | – | 0.03% | 220 |
|
|
2024
Q2 | $2.12M | Sell |
39,923
-8
| -0% | -$524 | 0.03% | 239 |
|
|
2024
Q1 | $3.27M | Buy |
39,931
+24,000
| +151% | +$1.07M | 0.04% | 227 |
|
|
2023
Q4 | $296K | Hold |
15,931
| – | – | ﹤0.01% | 288 |
|
|
2023
Q3 | $176K | Hold |
15,931
| – | – | ﹤0.01% | 298 |
|
|
2023
Q2 | $258K | Hold |
15,931
| – | – | ﹤0.01% | 290 |
|
|
2023
Q1 | $265K | Hold |
15,931
| – | – | ﹤0.01% | 289 |
|
|
2022
Q4 | $150K | Hold |
15,931
| – | – | ﹤0.01% | 295 |
|
|
2022
Q3 | $43K | Sell |
15,931
-1,000
| -6% | -$3.27K | ﹤0.01% | 322 |
|
|
2022
Q2 | $49K | Sell |
16,931
-1,150
| -6% | -$2.85K | ﹤0.01% | 320 |
|
|
2022
Q1 | $54K | Sell |
18,081
-7,042,722
| -100% | -$25.3M | ﹤0.01% | 340 |
|
|
2021
Q4 | $32.5M | Sell |
7,060,803
-932,408
| -12% | -$5.23M | 0.26% | 100 |
|
|
2021
Q3 | $50.2M | Buy |
7,993,211
+322,659
| +4% | +$1.99M | 0.39% | 74 |
|
|
2021
Q2 | $45.9M | Buy |
7,670,552
+21,700
| +0.3% | +$129K | 0.35% | 82 |
|
|
2021
Q1 | $48.4M | Sell |
7,648,852
-858,938
| -10% | -$6.04M | 0.36% | 77 |
|
|
2020
Q4 | $47.9M | Buy |
8,507,790
+519,155
| +6% | +$3.14M | 0.37% | 79 |
|
|
2020
Q3 | $46.5M | Sell |
7,988,635
-474,198
| -6% | -$3.27M | 0.44% | 66 |
|
|
2020
Q2 | $61M | Sell |
8,462,833
-361,693
| -4% | -$2.4M | 0.63% | 55 |
|
|
2020
Q1 | $41.3M | Buy |
8,824,526
+10,948
| +0.1% | +$67.3K | 0.54% | 62 |
|
|
2019
Q4 | $70.7M | Buy |
8,813,578
+682,050
| +8% | +$4.97M | 0.63% | 56 |
|
|
2019
Q3 | $55.9M | Buy |
8,131,528
+1,280,435
| +19% | +$9.51M | 0.56% | 62 |
|
|
2019
Q2 | $56.9M | Buy |
6,851,093
+2,351,889
| +52% | +$20.1M | 0.55% | 67 |
|
|
2019
Q1 | $44.7M | Buy |
4,499,204
+701,868
| +18% | +$5.87M | 0.42% | 75 |
|
|
2018
Q4 | $29.1M | Buy |
3,797,336
+926,249
| +32% | +$11.1M | 0.31% | 97 |
|
|
2018
Q3 | $50M | Buy |
2,871,087
+1,147,105
| +67% | +$13.7M | 0.42% | 83 |
|
|
2018
Q2 | $16.4M | Buy |
1,723,982
+95,231
| +6% | +$633K | 0.15% | 135 |
|
|
2018
Q1 | $7.12M | Buy |
+1,628,751
| New | +$9.01M | 0.07% | 201 |
|
Other funds holding VKTX
ArrowMark Colorado Holdings's VKTX Position: Q2 2026 in Review
ArrowMark Colorado Holdings reduced its Viking Therapeutics (VKTX) stake by 72% in Q2 2026, selling an estimated $808K and leaving 9,878 shares worth $385K. The position accounts for 0.02% of the portfolio, ranked #278.
ArrowMark Colorado Holdings first reported a position in VKTX in Q1 2018 and has held it in 34 quarters since. The position peaked at $70.7M in Q4 2019. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- ArrowMark Colorado Holdings held 9,878 shares of Viking Therapeutics worth $385K as of Q2 2026.
- ArrowMark Colorado Holdings sold 25,000 Viking Therapeutics shares in Q2 2026, an estimated $808K.
- Viking Therapeutics made up 0.02% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #278 holding.
- ArrowMark Colorado Holdings first reported a position in Viking Therapeutics in Q1 2018 and has held it in 34 quarters since.
- ArrowMark Colorado Holdings's Viking Therapeutics position peaked at $70.7M in Q4 2019.
- 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.